Therapeutic efficiency of trimetazide MR in patients with type 2 diabetes mellitus after myocardial infarction
https://doi.org/10.14341/2072-0351-5400
Abstract
Aim.
To evaluate efficiency of trimetazide MR combined with basic therapy of type 2 diabetes mellitus (DM2) in patients with myocardial infarction (MI).
Materials and methods.
The study included 106 patients with DM2 who underwent MI. Polycomponent basic therapy supplemented by trimetazideMR at a daily dose of 70 mg was given to 51 patients. The patients condition 6 and 12 months after treatment was evaluated from the results of echo-CG, 24 hr ECG monitoring, and 6 min walking test. Quality of life was estimated using modified Minnesota questionnaire scores.
Results.
Trimetazide MR combined with polycomponent basic therapy reduced consumption of nitroglycerine by DM2 patients after myocardial infarction,frequency of ventricular and supraventricular extrasystole in 25.3 and 25.3% of the cases respectively. Episodes of painless myocardial ischemiaoccurred only in 35.6% of the patients. Long-term treatment with trimetazide MR as a component of combined therapy increased injectionfraction in patients with abnormal myocardial contractility (p<0.05) and decreased the frequency of painless myocardial ischemia (p<0.05).
Conclusion.
Inclusion of trimetazide MR in a year-long polycomponent basic therapy of DM2 in patients with IM effectively prevented dysadaptiveremodelling of the heart and improved quality of life.
To evaluate efficiency of trimetazide MR combined with basic therapy of type 2 diabetes mellitus (DM2) in patients with myocardial infarction (MI).
Materials and methods.
The study included 106 patients with DM2 who underwent MI. Polycomponent basic therapy supplemented by trimetazideMR at a daily dose of 70 mg was given to 51 patients. The patients condition 6 and 12 months after treatment was evaluated from the results of echo-CG, 24 hr ECG monitoring, and 6 min walking test. Quality of life was estimated using modified Minnesota questionnaire scores.
Results.
Trimetazide MR combined with polycomponent basic therapy reduced consumption of nitroglycerine by DM2 patients after myocardial infarction,frequency of ventricular and supraventricular extrasystole in 25.3 and 25.3% of the cases respectively. Episodes of painless myocardial ischemiaoccurred only in 35.6% of the patients. Long-term treatment with trimetazide MR as a component of combined therapy increased injectionfraction in patients with abnormal myocardial contractility (p<0.05) and decreased the frequency of painless myocardial ischemia (p<0.05).
Conclusion.
Inclusion of trimetazide MR in a year-long polycomponent basic therapy of DM2 in patients with IM effectively prevented dysadaptiveremodelling of the heart and improved quality of life.
About the Authors
E E Novitskaya
ФГУ «Поликлиника №1» Управления делами Президента РФ, Москва
G A Baryshnikova
ФГУ «Учебно-научный медицинский центр Управления делами Президента РФ», Москва
References
1. Ferrari R. Healthy versus sick myocites: metabolism, structure and function. Eur Heart J Supplements 2002; 4(Suppl G): G1-G12.
2. Opie L, King L. Glucose and glycogen utilyzation in myocardial ischemia change in metabolism and consequence for myocyte. Mol. Cell. Biochem. 1998, 180:3-26.
3. Stanley W, Lopaschuk G, Hall J. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Cardiovasc. Res. 1997, 33: 243-257.
4. Ferrari R, Pedersim P, Bongrazio M. Mitochondrial energy production and cation control in myocardial ischaemia and reperfusion. Basic Res Cardiol 2003, 88:495-512.
5. Lopaschuk G Abnormal mechanical function in diabetes: relationship to altered myocardial carbohydrate/lipid metabolism. Coron Artery Dis, 1996;7(2):116-23.
6. Lopaschuk G, Wambolt R, Barr L. An imbalance between glycolysis and glucose oxidation in a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J. Pharm. Exp. Therap. 2006, 264:135-144.
7. Schwaiger M, Sun D, Deeb M. Expression of myocardial glucose transporter (GLUT) mRNAs in patients with advanced coronary artery disease. Circulation 1994, 90:101-113.
8. Szwed H., Pachoki R., Domzal-Bochelska M. et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOI-I. Cardiovasc Drug Ther. 1999; 13: 215-220.
Review
For citations:
Novitskaya E.E., Baryshnikova G.A. Therapeutic efficiency of trimetazide MR in patients with type 2 diabetes mellitus after myocardial infarction. Diabetes mellitus. 2009;12(2):58-61. (In Russ.) https://doi.org/10.14341/2072-0351-5400
Views:
3465
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
